There is a balance between Siglec-5 and Siglec-14; when Siglec-5 activity is enhanced, Siglec-14 activity is reduced, thus promoting hepatocellular carcinoma progression. This evidence concerns the gene SIGLEC14 and hepatocellular carcinoma.